Curi Bio Welcomes Greg Luerman, PhD as Vice President of Research & Partnerships
Luerman Brings Breadth of Scientific and Commercial Experience to Fast Growing Seattle Biotechnology Company
SEATTLE – Curi Bio Inc., a leading developer of human stem cell-based platforms for therapeutic discovery, announced today the appointment of Greg Luerman, PhD as Vice President, Research & Partnerships. Dr. Luerman will lead strategic business development and partnering activities, including driving commercial growth for services, instruments, and products at Curi Bio.
Dr. Luerman has spent his career as a strategic business and corporate development leader at large pharmaceutical companies and at global CRMOs. His deep industry insights and client-facing experiences will help provide leadership, strategy, and mentoring for Curi Bio’s quickly growing team. The company recently closed a $10 million oversubscribed Series A financing round to advance its 3D engineered muscle tissue products for drug discovery.
“We are very excited to have Dr. Greg Luerman join our team during this pivotal growth stage,” said Michael Cho, JD, CEO of Curi Bio. “His deep scientific and commercial experience in scaling organizations will be essential to advancing our rapidly expanding business and accelerating discovery timelines for our pharmaceutical customers.”
After earning his PhD from University of Louisville, Dr. Luerman's industry journey started with a Michael J Fox Foundation postdoctoral fellowship in Pfizer’s Neuroscience Research Unit. He followed with positions at ChanTest (acquired by Charles River), Axiogenesis, and Ncardia, where he managed stem cell-derived cardiac and neuroscience products and services. Dr. Luerman was most recently Director of Business Development and Strategic Alliances at Shanghai ChemPartner, a large global CRO/CDMO where his role focused on supporting large pharma R&D relationships.
“I am very energized by the momentum that Curi and its talented team bring to supporting the booming gene and cellular therapies market,” said Dr. Luerman. “Curi’s innovative biological and AI systems, instrumentation, and services are especially well-suited to bridge the gap in translational models the industry has sorely needed. These next-generation tools help guide our partners’ decision making to progress safe and effective therapies to the clinic for rare disease and personalized medicine approaches. It’s an exciting company culture and unique business model to be a part of!”
About Curi Bio
Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. The company’s proprietary technologies are supported by over 100 publications and 19 patents. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.
For more information, please visit www.curibio.com.
Contact Info
Heejoon Choi
Director of Sales & Marketing, Curi Bio
heejoon@curibio.com